Loss of function TET2 mutation (TET2 MT) is one of the most frequently observed lesions in
clonal haematopoiesis (CH). TET2 a member TET-dioxygenase family of enzyme that along …

The aim of our review has been to give an appropriate idea of analogies and differences
between primitive MDS (p-MDS) and t-MDS throughout an accurate reviewing of English …

Background Patients with chronic lymphocytic leukemia (CLL) have a higher risk of
developing other malignancies (OMs) compared to the general population. However, the …

Therapy-related myeloid neoplasms (tMN) are complications of cytotoxic therapies. Risk of
tMN is high in recipients of autologous hematopoietic stem cell transplantation (aHSCT) …

Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the
cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also …

Abstract Therapy-related Myeloid Neoplasm (t-MN) represents one of the worst long-term
consequences of cytotoxic therapy for primary tumors and autoimmune disease. Poor …

In chronic lymphocytic leukemia (CLL), analysis of TP53 aberrations (deletion and/or
mutation) is a crucial part of treatment decision-making algorithms. Technological and …

Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT)
used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has …

Therapy-related myeloid neoplasms (t-MN) arise after a documented history of
chemo/radiotherapy as treatment for an unrelated condition and account for 10–20% of …

Therapy-related myeloid neoplasms (t-MN) account for approximately 10–15% of all myeloid
neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to …